The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
Each company will share operational data with Evinova, feeding the platform’s AI engines to provide benchmarks and actionable insights, aiming to speed up trials while maintaining top-tier patient care
Iberdomide has the potential to be the first approved CELMoD agent
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
The pharma company will donate more than seven tons of its active pharmaceutical ingredient (API) to bolster the American supply chain
India plays a critical role in Bristol Myers Squibb’s global strategy
Subscribe To Our Newsletter & Stay Updated
